Denali Therapeutics Net Worth
Denali Therapeutics Net Worth Breakdown | DNLI |
Denali Therapeutics Net Worth Analysis
Denali Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Denali Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Denali Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Denali Therapeutics' net worth analysis. One common approach is to calculate Denali Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Denali Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Denali Therapeutics' net worth. This approach calculates the present value of Denali Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Denali Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Denali Therapeutics' net worth. This involves comparing Denali Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Denali Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Denali Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Denali Therapeutics' net worth research are outlined below:
| Denali Therapeutics generated a negative expected return over the last 90 days | |
| Denali Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Sato Vicki L of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 |
Denali Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Denali Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Denali Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Denali Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Denali Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Denali Therapeutics backward and forwards among themselves. Denali Therapeutics' institutional investor refers to the entity that pools money to purchase Denali Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.3 M | Alliancebernstein L.p. | 2024-06-30 | 2 M | Camber Capital Management Llc | 2024-09-30 | 2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.5 M | Principal Financial Group Inc | 2024-09-30 | 1.2 M | Baillie Gifford & Co Limited. | 2024-09-30 | 13.3 M | Blackrock Inc | 2024-06-30 | 13.2 M |
Follow Denali Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.51 B.Market Cap |
|
Project Denali Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
When accessing Denali Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Denali Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Denali Therapeutics' profitability and make more informed investment decisions.
Evaluate Denali Therapeutics' management efficiency
Denali Therapeutics has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.13. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Denali Therapeutics' Non Current Assets Total are increasing as compared to previous years. The Denali Therapeutics' current Non Currrent Assets Other is estimated to increase to about 19.1 M, while Total Assets are projected to decrease to under 932.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.50 | 13.43 | |
| Tangible Book Value Per Share | 7.50 | 13.43 | |
| Enterprise Value Over EBITDA | (15.96) | (15.17) | |
| Price Book Value Ratio | 2.86 | 2.17 | |
| Enterprise Value Multiple | (15.96) | (15.17) | |
| Price Fair Value | 2.86 | 2.17 | |
| Enterprise Value | 2.9 B | 2.1 B |
The decision-making processes within Denali Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 2.8 K | Quarterly Revenue Growth (1.00) | Return On Equity (0.35) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Denali Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denali Therapeutics Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 16th of August 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Denali Therapeutics Earnings per Share Projection vs Actual
Denali Therapeutics Corporate Management
| Peter Chin | Senior Affairs | Profile | |
| Carole MD | Chief Development | Profile | |
| Mark Rowen | Vice Development | Profile | |
| Chris Walsh | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.77) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.